ATMUS FILTRATION TECHNOLOGIES INC.
Atmus Filtration Technologies Inc. is engaged in filtration and media solutions. The Company designs and manufactures advanced filtration products, principally under the Fleetguard brand, that enable lower emissions and provide superior asset protection. It serves customers across the truck, bus, agriculture, construction, mining, marine and power generation vehicle, and equipment markets, along with providing comprehensive aftermarket support and solutions. Its products include fuel filters, lube filters, air filters, crankcase ventilation, hydraulic filters and coolants and other chemicals. It offers products for first fit and aftermarket applications to original equipment manufacturers, dealers/distributors, and end-users. The Company produces and sells Fleetguard branded products across North America, Europe, South America, Asia, Australia, and the African continents. Its Fleetguard branded products are available through distribution centers worldwide.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying ATMUS Filtration Technologies' stock, with a target price suggesting potential growth.
Financial Health
Atmus Filtration Technologies is performing well, with strong sales and cash generation.
Dividend
ATMUS Filtration Technologies' low dividend yield of 0.4% indicates limited returns for investors seeking dividends. If you invested $1000 you would be paid $4 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ATMU
The North Ablaze: Investing In Wildfire Resilience
This carefully selected group of stocks offers exposure to companies tackling Canada's unprecedented wildfire crisis. Our professional analysts have identified businesses positioned to benefit from increased spending on wildfire suppression, air quality solutions, and carbon monitoring technologies.
Published: July 21, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Growth via Partnerships
Atmus’s collaborations with pharmaceutical companies can scale revenue through licensed device‑drug pairings, though outcomes depend on regulatory success and commercial adoption.
Technology Edge
Proprietary inhalation and filtration technologies may differentiate offerings and attract deals, but R&D and regulatory risk mean results are uncertain.
Demand Drivers
Global respiratory disease trends and ageing populations support long‑term demand for delivery devices, although competition and reimbursement pressures remain considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
